IP Library Granted Patent US 8,606,342
Granted Patent B2
US 8,606,342 · App. 11/263,404 · Granted Dec 10, 2013

Pulse and active pulse spectraphotometry

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,606,342
App. No.
11/263,404
Granted
Dec 10, 2013
Kind
B2
Abstract

A pulse and active pulse spectraphotometry system comprises a light source adapted to illuminate a tissue site with optical radiation having a plurality of wavelengths selected from at least one of a primary band of about 1620 nm to about 1730 nm and a secondary band of about 1000 nm to about 1380 nm.

Claims (25)

1. A noninvasive optical sensor capable of outputting a signal usable by a patient monitor to determine one or more physiological parameters of a wearer of the optical sensor, the optical sensor comprising:

a light source configured to irradiate tissue at a single tissue location, the light source emitting optical radiation at a number of discrete wavelengths, the number of discrete wavelengths consisting of one wavelength from a first wavelength band in a range of about 1620 nm to about 1655 nm when the light source emits said optical radiation at wavelengths in the first wavelength band, and consisting of one wavelength from a second wavelength band in a range of about 1000 nm to about 1102 nm when the light source emits said optical radiation at wavelengths in the second wavelength band, and

a detector capable of detecting the optical radiation after attenuation by body tissue and of outputting a signal indicative of the attenuation by the body tissue, the signal being usable by a patient monitor to determine one or more measurement values for blood glucose of the body tissue.

2. The noninvasive optical sensor according to claim 1 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1650 nm±5 nm when the light source emits said optical radiation at wavelengths in the first wavelength band.

3. The noninvasive optical sensor according to claim 1 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1032 nm±5 nm when the light source emits said optical radiation at wavelengths in the second wavelength band.

4. The noninvasive optical sensor according to claim 1 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1097 nm±5 nm when the light source emits said optical radiation at wavelengths in the second wavelength band.

5. The noninvasive optical sensor according to claim 1 wherein the number of discrete wavelengths consists of one wavelength from a third wavelength band in a range of about 2000 nm to about 2500 nm when the light source emits said optical radiation at wavelengths in the third wavelength band.

6. A method of operating a noninvasive physiological sensor to acquire a signal indicative of one or more physiological parameters of body tissue, the method comprising:

illuminating a single measurement site of body tissue with optical radiation at a number of discrete wavelengths from a light source of said sensor, the number of discrete wavelengths consisting of one wavelength selected from a first wavelength band in a range of about 1620 nm to about 1655 nm when the light source emits said optical radiation at wavelengths in the first wavelength band, and consisting of one wavelength selected from a second wavelength band in a range of about 1000 nm to about 1102 nm when the light source emits said optical radiation at wavelengths in the second wavelength band;

detecting the optical radiation after attenuation by the body tissue, said detecting using an optical detector; and

outputting from said detector a signal indicative of the attenuation, the signal being usable by a patient monitor to determine one or more measurement values for blood glucose of the body tissue.

7. The method according to claim 6 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1650 nm±5 nm when the light source emits said optical radiation at wavelengths in the first wavelength band.

8. The method according to claim 6 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1032 nm±5 nm when the light source emits said optical radiation at wavelengths in the second wavelength band.

9. The method according to claim 6 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1097 nm±5 nm when the light source emits said optical radiation at wavelengths in the second wavelength band.

10. The method according to claim 6 wherein the number of discrete wavelengths consists of one wavelength selected from a third wavelength band in a range of about 2000 nm to about 2500 nm when the light source emits said optical radiation at wavelengths in the third wavelength band.

11. A patient monitoring system, comprising:

means for illuminating a single measurement site of body tissue with optical radiation at a number of narrowbands, the number of narrowbands consisting of one narrowband selected from a first wavelength band in a range of about 1620 nm to about 1655 nm when emitting said optical radiation at narrowbands in the first wavelength band, and consisting of one narrowband selected from a second wavelength band in a range of about 1000 nm to about 1102 nm when emitting said optical radiation at narrowbands in the second wavelength band; and

means for detecting the optical radiation after attenuation by the body tissue and outputting a signal indicative of the attenuation, the signal being usable by a patient monitor to determine one or more measurement values for blood glucose of the body tissue.

12. The patient monitoring system according to claim 11 wherein the number of narrowbands consists of one narrowband from a range of about 1650 nm±5 nm when emitting said optical radiation at narrowbands in the first wavelength band.

13. The patient monitoring system according to claim 11 wherein the number of narrowbands consists of one narrowband from a range of about 1032 nm±5 nm when emitting said optical radiation at narrowbands in the second wavelength band.

14. The patient monitoring system according to claim 11 wherein the number of narrowbands consists of one narrowband from a range of about 1097 nm±5 nm when emitting said optical radiation at narrowbands in the second wavelength band.

15. A noninvasive optical sensor capable of outputting a signal usable by a patient monitor to determine one or more physiological parameters of a wearer of the optical sensor, the optical sensor comprising:

a light source configured to irradiate tissue at a single tissue location, the light source emitting optical radiation at a number of discrete wavelengths, the number of discrete wavelengths consisting of one wavelength from a first wavelength band in a range of about 1620 nm to about 1655 nm when the light source emits said optical radiation at wavelengths in the first wavelength band, and consisting of one wavelength from a second wavelength band in a range of about 1375 nm±5 nm when the light source emits said optical radiation at wavelengths in the second wavelength band, and

a detector capable of detecting the optical radiation after attenuation by body tissue and of outputting a signal indicative of the attenuation by the body tissue, the signal being usable by a patient monitor to determine one or more measurement values for blood glucose of the body tissue.

16. The noninvasive optical sensor according to claim 15 wherein the number of discrete wavelengths consists of one wavelength from a range of about 1650 nm±5 nm when the light source emits said optical radiation at wavelengths in the first wavelength band.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2016
From: CERCACOR LABORATORIES, INC.
To: MASIMO CORPORATION
Reel/Frame 038049/0074 →
CHANGE OF NAME Recorded May 11, 2012
From: MASIMO LABORATORIES, INC.
To: CERCACOR LABORATORIES, INC.
Reel/Frame 028192/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2007
From: MASIMO CORPORATION
To: MASIMO LABORATORIES, INC.
Reel/Frame 019580/0133 →